Clarisse Dromain’s Post

Whole-body SPECT imaging is a powerful diagnostic tool that combines functional and anatomical information to provide detailed insights into the entire body. It is particularly valuable in detecting and monitoring diseases such as metastatic cancer, bone disorders, and certain neurological conditions. This imaging modality uses radiotracers to highlight areas of abnormal metabolic activity, helping clinicians make accurate diagnoses and guide targeted treatments. The ability to visualize functional changes at a molecular level makes SPECT a cornerstone in personalized medicine. Excited to continue exploring the advancements in nuclear medicine and their impact on patient care! 🚀 #NuclearMedicine #SPECT #WholeBodyScan #MedicalImaging #ProfessionalGrowth

Check out our newly updated course; Neuroendocrine Tumour Imaging and Molecular Radiotherapy. Intended for radiologists and nuclear medicine physicians, this eLearning course aims to explore the diverse group of these relatively rare cancers. Course Highlights👇 🔷explore the concept of somatostatin receptor imaging 🔷examine the clinical indications for performing 68 Ga DOTA-SSA PET-CT and its use in evaluating recurrence 🔷deep dive into the role of 18FDG PET-CT in high and low-grade NETs 🔷advance your expertise and improve patient outcomes To register 👉 https://bit.ly/NETsImaging Our courses are available to Alliance Medical Ltd and #NHS NC1 Staff. #neuroendocrine #NETsCancer #radiologist #PETCT

Did You Know? The Story of Iodine-131 🧬 Discovered over 80 years ago in 1938, Iodine-131 has remained a cornerstone of modern nuclear medicine. This radioactive isotope has been a game-changer, particularly in treating thyroid disorders, such as hyperthyroidism and thyroid cancer. But how does it work? 🤔 Once administered, Iodine-131 travels directly to the thyroid, where it emits radiation to selectively destroy overactive or cancerous thyroid cells. This precision allows for targeted treatment, reducing the need for invasive surgery and minimizing side effects. ✨ 🌟 Still in Use Today: Fast forward to today, and Iodine-131 is still widely used around the world, proving its lasting impact on healthcare. It’s trusted by physicians because of its effectiveness, safety, and ability to provide long-term results. From shrinking overactive thyroids to eradicating cancer cells, this small but powerful isotope continues to save lives. 🌍 A Global Legacy: Used in hospitals and clinics globally, Iodine-131 remains a prime example of how early scientific breakthroughs continue to drive modern medicine forward. Its applications have expanded, and it now helps millions of people lead healthier lives with fewer complications. From 1938 to 2024, Iodine-131’s story is one of longevity, innovation, and healing. It’s amazing how a discovery from decades ago continues to play such a critical role in thyroid health today! 🙌 #Iodine131 #ThyroidHealth #NuclearMedicine #ThyroidTreatment #Radiopharmaceuticals #MedicalInnovation #FunFactFriday #HealthcareRevolution #IMS

Nuclear physics is pivotal in the field of medicine, with key applications in diagnostics and therapy. This includes PET and SPECT scans for cancer detection, targeted radiotherapy for cancer cells, and radiopharmaceutical treatments like iodine-131 for thyroid cancer. Diagnostic tests such as Bone Scans and Thyroid Scans are crucial for assessing bone diseases and thyroid function. Ongoing research in nuclear medicine aims to enhance treatment methods and develop new radiopharmaceuticals. Safety and regulations are paramount for the proper handling of radioactive materials to ensure patient and provider safety. Understanding these principles is essential for advancing medical technologies and improving patient outcomes. #Medical_Physics #Nuclear_physics #Radiopharmaceutical

🎉 The UK's first XEOS Aura 10 has received glowing reviews during trials at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust. ⏱️ The Aura 10 allows surgeons to assess tumour margins in real-time, directly in theatre, and in as little as 10 minutes. Head of nuclear medicine, Lisa Rowley, said: “… the potential of the AURA 10 to deliver improved outcomes for our patients will be a real game changer.” MaxilloFacial Consultant Gary Walton, who is also Assistant Medical Director for Cancer at the Trust, said: “It’s much quicker than the usual margin resection and it means that patients don’t need to have adjuvant treatment (such as chemotherapy or radiotherapy), which they would otherwise need.” Learn more about the trial here: https://lnkd.in/edRyZsAW

The October 2024 issue of The Journal of Nuclear Medicine - JNM is out now! Highlights include: >Is Chat GPT a Reliable Ghostwriter? >Commentary: Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics Through the Lens of RELAINCE >The State of the Art: The Rise of Molecular Image–Guided Robotic Surgery >Is It Really Happening? 1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening? >FEATURED: [68Ga]Ga-RAYZ-8009: A Glypican-3–Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging—A First-in-Human Case Series >FEATURED: The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE >...and more! https://lnkd.in/eZS7x8M2

Hi everyone As it was known at recent WHO classification of CNS tumors has emerged various number of classifications which helps in making diagnosis easy and reliable. A nice case has been diagnosed. A patient has been referred to us with a clinical history of imbalance while walking associated with spasticity in the lower limbs with extensor plantars and exaggerated deep tendon reflexes. MRI revealed cystic lesions along the leptomeningeal surfaces of cerebellum perilesional edema associated with significant contrast enhancement. The lesions were hyperintense in T1 with hydrocephalus and spinal part shows a large focal cystic lesion associated with thick irregular leptomeningeal enhancement. Robotic Biopsy revealed round cells with bland nuclear chromatin and perinuclear halos with inconspicuous nucleoli associated with mitotic activity. Focal neuronal differentiation was seen. Some areas showed vacuolated microcystic changes with myxoid material. IHC Shows tumor is positive for GFAP & S100. Based on above findings the diagnosis of Leptomeningeal Tumor was given as per recent WHO classification. Karyotyping was done and it shows 48,X,−Y,+7,+12,+17 #sterotypic #brain #robotic #biopsies #karyotyping #rare #case #with #spinal #discordant

Weekly thoracic MDT dealing with lung , thymus, metastatic disease and mediastinal tumors. With team involving surgeons, oncologists, radiologists, pulmonologists, pathologists and nuclear medicine. More to come 🤲 #egypt #assiut #lungcancer #MDT #screening #decisionmaking

Nickel-60 can be used to produce cobalt-57, which is mainly used in medicine, industry and scientific research. In the medical field, cobalt-57 can be used to treat cancer, especially prostate cancer and cervical cancer. In addition, cobalt-57 can also be used in nuclear medicine examinations such as positron emission tomography (PET). In industry, cobalt-57 can be used in non-destructive testing, thickness measurement and density measurement. In the field of scientific research, cobalt-57 can be used to study the physical and chemical properties of substances, such as measuring parameters such as thermal conductivity and elastic modulus of materials. Please let me know if you need me. Email: catherine@abamtc.com Tel: +86 18751555734 Company website: https://lnkd.in/exFG_Pmt #Nickel #Cobalt #Co_57 #Ni_60 #Amber_Bridge #Isotopic_Gas #Isotope #Medical_Field #Industrial_Field #PET #Density_Measurement

The current treatments for brain tumors are invasive and, in many cases, insufficient. The future of theranostics in neurooncology is promising, but more research and trials are needed to increase the permeability of the brain blood barrier – one of the biggest obstacles to eradicating brain tumors. This article, published earlier this year in The Journal of Nuclear Medicine - JNM, outlines the future of theranostics in treating four of the most common brain tumors. Read the entire article here:  https://lnkd.in/gnBUdxuC